Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

89 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Curcumin and chronic kidney disease (CKD): major mode of action through stimulating endogenous intestinal alkaline phosphatase.
Ghosh SS, Gehr TW, Ghosh S. Ghosh SS, et al. Among authors: gehr tw. Molecules. 2014 Dec 2;19(12):20139-56. doi: 10.3390/molecules191220139. Molecules. 2014. PMID: 25474287 Free PMC article. Review.
Triamterene and the kidney.
Sica DA, Gehr TW. Sica DA, et al. Among authors: gehr tw. Nephron. 1989;51(4):454-61. doi: 10.1159/000185375. Nephron. 1989. PMID: 2662034 Review.
The pharmacokinetics and pharmacodynamics of fosinopril in haemodialysis patients.
Gehr TW, Sica DA, Grasela DM, Duchin KL. Gehr TW, et al. Eur J Clin Pharmacol. 1993;45(5):431-6. doi: 10.1007/BF00315514. Eur J Clin Pharmacol. 1993. PMID: 8112372 Clinical Trial.
Colloid infusions reduce glomerular filtration in resuscitated burn victims.
Gore DC, Dalton JM, Gehr TW. Gore DC, et al. Among authors: gehr tw. J Trauma. 1996 Mar;40(3):356-60. doi: 10.1097/00005373-199603000-00005. J Trauma. 1996. PMID: 8601849 Clinical Trial.
Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.
Sica DA, Gehr TW, Fernandez A. Sica DA, et al. Among authors: gehr tw. Drug Saf. 2000 May;22(5):350-60. doi: 10.2165/00002018-200022050-00003. Drug Saf. 2000. PMID: 10830252 Review.
Pharmacokinetics and blood pressure response of losartan in end-stage renal disease.
Sica DA, Halstenson CE, Gehr TW, Keane WF. Sica DA, et al. Among authors: gehr tw. Clin Pharmacokinet. 2000 Jun;38(6):519-26. doi: 10.2165/00003088-200038060-00005. Clin Pharmacokinet. 2000. PMID: 10885588 Clinical Trial.
The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease.
Sica DA, Gehr TW. Sica DA, et al. Among authors: gehr tw. J Renin Angiotensin Aldosterone Syst. 2002 Dec;3(4):247-54. doi: 10.3317/jraas.2002.046. J Renin Angiotensin Aldosterone Syst. 2002. PMID: 12584668 Review.
Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations.
Sica DA, Gehr TW. Sica DA, et al. Among authors: gehr tw. Curr Opin Nephrol Hypertens. 2003 Mar;12(2):123-31. doi: 10.1097/00041552-200303000-00001. Curr Opin Nephrol Hypertens. 2003. PMID: 12589171 Review.
Aldosterone-receptor antagonism and end-stage renal disease.
McLaughlin N, Gehr TW, Sica DA. McLaughlin N, et al. Among authors: gehr tw. Curr Hypertens Rep. 2004 Aug;6(4):327-30. doi: 10.1007/s11906-004-0029-1. Curr Hypertens Rep. 2004. PMID: 15257869
Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
Brophy DF, Martin EJ, Gehr TW, Carr ME Jr. Brophy DF, et al. Among authors: gehr tw. Am J Kidney Dis. 2004 Aug;44(2):270-7. doi: 10.1053/j.ajkd.2004.04.032. Am J Kidney Dis. 2004. PMID: 15264185
89 results
Jump to page
Feedback